Ann: CSL Results Announcement, page-5

Month 00, 0000

CSL delivered another strong year, with reported net profit after tax of $2,103 million, up

22
17% at CC and revenue up 9% at CC , reflecting;

19 August 2020





o Solid growth in the immunoglobulin portfolio
o Successful evolution of haemophilia portfolio, driven by IDELVION®
o Transition to own distribution model in China
o Delivery on product differentiation strategy with strong profit growth for

Seqirus
o No material revenue impact to-date resulting from the COVID-19 pandemic,

however, the situation is fluid and some elements are unpredictableEarnings per share $4.63, up 17% at CC2
Final dividend3 of US$1.07 per share (approximately A$1.48)

o Total full year dividend increased to US$2.02 per share, up 9%
o Converted to Australian currency, the total full year dividend is approximately

A$2.95 per share, up 11%
Net profit after tax for FY21 is anticipated to be in the range of approximately $2,100million to $2,265 million at constant currency

o A key variable to this outlook is the uncertain impact of COVID-19 on theCompany’s supply chain, particularly the ability to collect plasma

o In response to the global pandemic, the Company urgently deployed itscapabilities, competencies and assets to support the global R&D effort, andnow has one vaccine partnership and four therapeutic candidates underinvestigation and development. Today’s profit outlook takes into account thisadditional research and development expense